Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Fortelyzin in Severe COVID-19
NCT05135546Phase 3Terminated
- Sponsor
- SuperGen, Inc.
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of staphylokinase in coronavirus disease 2019 (COVID-19), sponsored by SuperGen, Inc.. Started Dec 2021; status: terminated.
02
Drugs
staphylokinase
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05135546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135546.